Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Inclusion Criteria:

* Cytologically or histologically confirmed non-small cell lung cancer meeting the following criteria:

  * No T2 lesions invading the visceral pleura, causing atelectasis, or proximal to an obstructing pneumonia
  * No T3 lesions invading the chest wall (including the parietal pleura, musculature, and/or rib), mediastinal pleura, diaphragm, or pericardium
  * No T4 lesions invading the heart, great vessels, carina, or esophagus
* Must have disease that is incurable by standard treatment, defined as a minimum of first-line therapy with a platinum-containing regimen and second-line therapy with docetaxel, pemetrexed disodium, or erlotinib hydrochloride
* Measurable or nonmeasurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Life expectancy ≥ 12 weeks
* Hemoglobin ≥ 9.0 g/dL
* Absolute neutrophil count (ANC) ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Serum creatinine ≤ 3.0 mg/dL
* Total bilirubin \< 1.5 times upper limit of normal
* International normalized ratio (INR) ≤ 1.3
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective non-hormonal contraception

Exclusion Criteria:

* Superior vena cava syndrome or superior sulcus tumors
* Patients with airway obstructing lesions, or patients experiencing hemoptysis, dyspnea, chest pain, and/or copious sputum production may be eligible after careful consideration by the study physicians
* Prior or concurrent malignancy except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, stage I carcinoma of the prostate with normal PSA, or other cancer from which the patient has been disease free for 3 years
* Medical conditions that would make this protocol unreasonably hazardous, in the opinion of the treating physician, including any of the following:

  * Uncontrolled infection (including HIV)
  * Poorly controlled diabetes mellitus
  * Active cardiac disease (i.e., unstable angina, myocardial infarction within the past 6 months, or congestive heart failure)
* Other serious medical illness that would limit survival to \< 3 months, or psychiatric condition that would prevent informed consent, unless a legal guardian is available
* Must consent to participate in the laboratory study, "Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors" during course 1
* More than 6 months since prior gemcitabine hydrochloride

  * More than 2 weeks since other prior chemotherapy
* More than 4 weeks since prior radiotherapy